SARS-CoV-2 viral dynamics in non-human primates.
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
16
09
2020
accepted:
11
02
2021
revised:
29
03
2021
pubmed:
18
3
2021
medline:
15
4
2021
entrez:
17
3
2021
Statut:
epublish
Résumé
Non-human primates infected with SARS-CoV-2 exhibit mild clinical signs. Here we used a mathematical model to characterize in detail the viral dynamics in 31 cynomolgus macaques for which nasopharyngeal and tracheal viral load were frequently assessed. We identified that infected cells had a large burst size (>104 virus) and a within-host reproductive basic number of approximately 6 and 4 in nasopharyngeal and tracheal compartment, respectively. After peak viral load, infected cells were rapidly lost with a half-life of 9 hours, with no significant association between cytokine elevation and clearance, leading to a median time to viral clearance of 10 days, consistent with observations in mild human infections. Given these parameter estimates, we predict that a prophylactic treatment blocking 90% of viral production or viral infection could prevent viral growth. In conclusion, our results provide estimates of SARS-CoV-2 viral kinetic parameters in an experimental model of mild infection and they provide means to assess the efficacy of future antiviral treatments.
Identifiants
pubmed: 33730053
doi: 10.1371/journal.pcbi.1008785
pii: PCOMPBIOL-D-20-01686
pmc: PMC8007039
doi:
Substances chimiques
Antiviral Agents
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008785Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: A.G. PhD grant has been provided by ROCHE Company. J.G. has worked as consultant for ROCHE Company.
Références
Stat Med. 2011 May 10;30(10):1045-56
pubmed: 21337592
AAPS J. 2020 Feb 13;22(2):48
pubmed: 32060662
J Theor Biol. 2014 Apr 21;347:63-73
pubmed: 24440713
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Infect Dis Now. 2021 Jan 18;:
pubmed: 33521775
PLoS Comput Biol. 2021 Mar 1;17(3):e1008752
pubmed: 33647008
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Nature. 2007 Jan 18;445(7125):319-23
pubmed: 17230189
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
PLoS Med. 2018 Mar 27;15(3):e1002535
pubmed: 29584730
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
N Engl J Med. 2020 Aug 27;383(9):885-886
pubmed: 32530584
EBioMedicine. 2020 Oct;60:102976
pubmed: 32971472
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
PLoS Comput Biol. 2012;8(6):e1002588
pubmed: 22761567
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):8847-8852
pubmed: 28765371
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
Nature. 2020 Sep;585(7826):584-587
pubmed: 32698191
J Virol. 2006 Aug;80(15):7590-9
pubmed: 16840338
Immunol Rev. 2018 Sep;285(1):9-25
pubmed: 30129208
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nat Commun. 2018 Oct 1;9(1):4013
pubmed: 30275474
PLoS Pathog. 2009 Oct;5(10):e1000604
pubmed: 19798428